Form 4: PROCEPT BioRobotics CFO Sells Shares for Tax Obligations

PROCEPT BioRobotics' EVP and CFO, Kevin Waters, sold 706 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Kevin Waters, the Executive Vice President and Chief Financial Officer of PROCEPT BioRobotics Corp (PRCT), reported a transaction.
• On March 17, 2026, Waters sold 706 shares of PROCEPT BioRobotics Common Stock.
• The shares were sold at a price of $28.1532 per share.
• The purpose of this sale was to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Kevin Waters beneficially owns 151,558 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was non-discretionary and solely for tax withholding purposes related to RSU vesting, which is a routine part of executive compensation.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• Kevin Waters, EVP, CFO, sold shares to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Industry Context

StockSavvy.ai notes that insider sales to cover tax obligations upon RSU vesting are a common and routine occurrence across all industries, typically not indicative of a change in management's confidence in the company's future prospects. This transaction aligns with standard executive compensation practices.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes, not signaling a change in company fundamentals or management's outlook.

Key Dates

Recommendation

The transaction reported is a routine, non-discretionary sale of shares by an executive to cover tax obligations associated with RSU vesting. This type of insider sale does not typically reflect a change in the executive's confidence in the company or its future prospects, nor does it alter the fundamental investment thesis for PROCEPT BioRobotics. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to warrant a change in investment stance.

Keywords

PROCEPT BioRobotics, PRCT, Kevin Waters, Insider Transaction, Form 4, Stock Sale, Tax Withholding, RSU Vesting, CFO